Drugs / Elsamitrucin
Elsamitrucin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00184080 | May 2004 → Apr 2006 | non-Hodgkin lymphoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00090090 | Apr 2004 → Oct 2006 | chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elsamitrucin | “Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma” NCT00184080 ↗ |
| Known as | BBM-2478A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106409 ↗ |
| Known as | BMY-28090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106409 ↗ |
| Known as | Elsamitrucina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106409 ↗ |
| Known as | Elsamitrucine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106409 ↗ |
| Known as | NSC-369327 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106409 ↗ |
| Known as | SPI 28090 | “Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma” NCT00090090 ↗ |